These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

128 related items for PubMed ID: 36740768

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Sequential monitoring of cancer immunotherapy trial with random delayed treatment effect.
    Wu J, Zhu L, Li Y.
    J Biopharm Stat; 2023 Dec 25; ():1-14. PubMed ID: 38146192
    [Abstract] [Full Text] [Related]

  • 3. Robust group sequential designs for trials with survival endpoints and delayed response.
    Ghosh P, Ristl R, König F, Posch M, Jennison C, Götte H, Schüler A, Mehta C.
    Biom J; 2022 Feb 25; 64(2):343-360. PubMed ID: 34935177
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Statistical and practical considerations in designing of immuno-oncology trials.
    Mukhopadhyay P, Huang W, Metcalfe P, Öhrn F, Jenner M, Stone A.
    J Biopharm Stat; 2020 Nov 01; 30(6):1130-1146. PubMed ID: 33706684
    [Abstract] [Full Text] [Related]

  • 6. Group sequential design with maximin efficiency robust test for immunotherapy with generalized delayed treatment effect.
    Li B, Zhang J, Yang W, Su L, Yan F.
    Pharm Stat; 2024 Nov 01; 23(1):107-133. PubMed ID: 37859531
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Cancer immunotherapy trial design with cure rate and delayed treatment effect.
    Wei J, Wu J.
    Stat Med; 2020 Mar 15; 39(6):698-708. PubMed ID: 31773770
    [Abstract] [Full Text] [Related]

  • 10. Interim analysis based on the weighted log-rank test for delayed treatment effects under staggered patient entry.
    Yoshida M, Matsuyama Y.
    J Biopharm Stat; 2016 Mar 15; 26(5):842-58. PubMed ID: 26391147
    [Abstract] [Full Text] [Related]

  • 11. Properties of the weighted log-rank test in the design of confirmatory studies with delayed effects.
    Jiménez JL, Stalbovskaya V, Jones B.
    Pharm Stat; 2019 May 15; 18(3):287-303. PubMed ID: 30592138
    [Abstract] [Full Text] [Related]

  • 12. Design and analysis of group-sequential clinical trials based on a modestly weighted log-rank test in anticipation of a delayed separation of survival curves: A practical guidance.
    Magirr D, Jiménez JL.
    Clin Trials; 2022 Apr 15; 19(2):201-210. PubMed ID: 35257619
    [Abstract] [Full Text] [Related]

  • 13. On information fraction for Fleming-Harrington type weighted log-rank tests in a group-sequential clinical trial design.
    Kundu MG, Sarkar J.
    Stat Med; 2021 May 10; 40(10):2321-2338. PubMed ID: 33624861
    [Abstract] [Full Text] [Related]

  • 14. Weighted log-rank test for time-to-event data in immunotherapy trials with random delayed treatment effect and cure rate.
    Liu S, Chu C, Rong A.
    Pharm Stat; 2018 Sep 10; 17(5):541-554. PubMed ID: 30058101
    [Abstract] [Full Text] [Related]

  • 15. A unified approach to power and sample size determination for log-rank tests under proportional and nonproportional hazards.
    Tang Y.
    Stat Methods Med Res; 2021 May 10; 30(5):1211-1234. PubMed ID: 33819109
    [Abstract] [Full Text] [Related]

  • 16. A weighted log-rank test and associated effect estimator for cancer trials with delayed treatment effect.
    Yu C, Huang X, Nian H, He P.
    Pharm Stat; 2021 May 10; 20(3):528-550. PubMed ID: 33427400
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Sample size determination for the weighted log-rank test with the Fleming-Harrington class of weights in cancer vaccine studies.
    Hasegawa T.
    Pharm Stat; 2014 May 10; 13(2):128-35. PubMed ID: 24497461
    [Abstract] [Full Text] [Related]

  • 19. Determining the late effect parameter in the Fleming-Harrington test using asymptotic relative efficiency in cancer immunotherapy clinical trials.
    Kaneko Y, Morita S.
    J Biopharm Stat; 2024 Aug 10; 34(5):626-645. PubMed ID: 37585719
    [Abstract] [Full Text] [Related]

  • 20. Cancer immunotherapy trial design with random delayed treatment effect and cure rate.
    Wu J, Wei J.
    Stat Med; 2022 Feb 20; 41(4):786-797. PubMed ID: 34779534
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.